JATT III Acquisition Corp Ordinary Shares

Análisis de la acción JATT III Acquisition Corp Ordinary Shares (JTTT)

$10.300

0.000 (0.00%)Al cierre

Loading chart…
Máximo
10.320
Apertura
10.250
Precio medio ponderado por volumen
10.28
Volumen
5.85K
Capitalización
—
Mínimo
10.213
Importe
60.10K
EV/EBITDA, TTM
0.00

JATT III Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any business combination target, and the Company has not initiated any substantive discussions, directly or indirectly, with any business combination target. The Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. The Company is not engaged in any business operations and has not generated any revenue.

Análisis de IA of JATT III Acquisition Corp Ordinary Shares (JTTT)

Mantener

JTTT is not a strong buy right now due to its low RSI of 37.401, indicating potential oversold conditions, and a current price of 10.30, which is close to its 52-week low of 10.00. The stock has shown a 20-day change of -4.63%, suggesting a downward trend. However, the projected final change of +1047.66% based on historical patterns indicates potential for significant upside in the long term. The main risk is its current ratio of 0.28, indicating liquidity concerns.

Métricas de valoración

El PER previsto actual de JATT III Acquisition Corp Ordinary Shares (JTTT) es 0.00, frente a su media de 5 años de .

PER previsto

Media 5A P/E
P/E actual
0.00

EV/EBITDA previsto

Media 5A EV/EBITDA
EV/EBITDA actual
0.00

Precio/ventas previsto

Media 5A P/S
P/S actual
0.00

Cronología de eventos

2026-09-21 (ET)

16:00:00

Nscale Limited Files for IPO, Plans to List on NYSE

Preguntas frecuentes sobre JTTT, respondidas por Alphio AI

JATT III Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any business combination target, and the Company has not initiated any substantive discussions, directly or indirectly, with any business combination target. The Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. The Company is not engaged in any business operations and has not generated any revenue.

JTTT is not a strong buy right now due to its low RSI of 37.401, indicating potential oversold conditions, and a current price of 10.30, which is close to its 52-week low of 10.00. The stock has shown a 20-day change of -4.63%, suggesting a downward trend. However, the projected final change of +1047.66% based on historical patterns indicates potential for significant upside in the long term. The main risk is its current ratio of 0.28, indicating liquidity concerns.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar